Skip to main content
. 2013 Mar 8;8(3):e58234. doi: 10.1371/journal.pone.0058234

Table 1. Differences in age and sex specific mumps seroprevalence with 95% confidence intervals (CI) between the Pienter1 and Pienter2 study.

Seroprevalence Pienter1 Seroprevalence Pienter2
Age n Total (%) 95% CI Males (%) 95% CI Females (%) 95% CI n Total (%) 95% CI Males (%) 95% CI Females (%) 95% CI
0–1 months 51 73 (54–92) 52 (27–77) 83 (66–99) 16 79 (47–100) 55 (3–100) 95 (83–100)
2–3 months 84 39 (25–53) 41 (21–60) 38 (20–55) 63 53 (37–69) 44 (24–65) 62 (37–86)
4–5 months 113 30 (17–42) 34 (12–55) 25 (15–36) 53 7 (0–13) 6 (0–15) 7 (0–18)
6–9 months 251 6 (2–10) 4 (0–8) 10 (2–18) 137 1 (0–3) 0 3 (0–6)
10–13 months 192 8 (3–13) 4 (0–9) 12 (4–21) 96 6 (0–13) 5 (0–14) 8 (0–19)
14–16 months 57 37 (24–49) 49 (32–65) 23 (7–39) 30 62 (46–78) 61 (40–83) 63 (40–86)
17–23 months 117 92 (88–97) 91 (84–98) 93 (87–100) 58 87 (76–97) 88 (72–100) 86 (72–99)
2 189 89 (85–94) 91 (85–96) 88 (81–95) 117 90 (85–95) 86 (77–95) 95 (90–100)
3 226 93 (90–96) 91 (86–97) 95 (91–99) 143 84 (78–90) 79 (69–90) 88 (81–95)
4 156 91 (87–96) 95 (91–100) 86 (78–95) 146 82 (76–88) 78 (69–87) 86 (77–95)
5 106 88 (82–94) 89 (81–97) 88 (78–97) 95 83 (77–89) 86 (76–96) 78 (67–89)
6 122 92 (87–97) 92 (85–99) 92 (84–99) 107 76 (67–85) 72 (58–86) 81 (70–92)
7 102 89 (83–95) 90 (81–99) 88 (80–96) 129 72 (64–79) 61 (49–72) 85 (75–95)
8 130 94 (90–98) 93 (86–100) 96 (91–100) 129 71 (62–81) 68 (55–80) 75 (63–88)
9 97 98 (96–100) 98 (95–100) 98 (95–100) 160 93 (88–98) 93 (85–100) 92 (84–100)
10 114 97 (95–100) 97 (93–100) 97 (94–100) 85 96 (92–100) 94 (85–100) 98 (94–100)
11 111 96 (93–100) 96 (92–100) 96 (90–100) 96 95 (90–99) 93 (86–100) 96 (90–100)
12 125 93 (86–100) 86 (68–100) 98 (95–100) 92 90 (84–96) 87 (77–97) 94 (87–100)
13 126 95 (91–99) 93 (86–100) 97 (94–100) 78 91 (85–96) 91 (83–99) 89 (77–100)
14 102 97 (94–100) 97 (93–100) 98 (93–100) 81 94 (89–99) 94 (87–100) 94 (87–100)
15 108 94 (90–98) 95 (89–100) 94 (88–100) 65 87 (78–95) 86 (75–97) 87 (74–100)
16–18 278 96 (94–99) 94 (90–98) 99 (97–100) 186 87 (83–92) 85 (76–93) 90 (84–95)
19–21 207 92 (88–97) 93 (87–99) 92 (86–99) 223 87 (82–92) 87 (78–97) 87 (82–92)
22–24 198 95 (92–98) 96 (92–100) 95 (90–99) 188 92 (87–96) 95 (89–100) 88 (82–95)
25–27 232 96 (93–99) 98 (95–100) 94 (90–98) 203 91 (86–96) 95 (88–100) 87 (82–93)
28–30 214 93 (90–97) 90 (84–97) 98 (95–100) 202 91 (86–96) 90 (84–96) 91 (85–98)
31–34 363 95 (91–98) 95 (91–99) 95 (91–98) 277 93 (90–96) 95 (90–100) 91 (87–96)
35–39 500 95 (93–97) 95 (92–98) 95 (92–98) 381 93 (90–96) 94 (91–97) 92 (88–96)
40–44 478 97 (95–99) 96 (92–99) 98 (97–100) 309 95 (93–98) 93 (89–97) 98 (96–100)
45–49 468 97 (96–99) 97 (95–99) 98 (96–100) 332 97 (94–99) 97 (93–100) 97 (94–99)
50–54 494 97 (95–99) 96 (91–100) 98 (96–100) 365 94 (92–97) 91 (86–96) 98 (96–100)
55–59 501 97 (95–99) 97 (94–99) 97 (94–100) 349 97 (95–99) 96 (92–100) 98 (96–100)
60–64 452 98 (97–100) 98 (96–100) 98 (97–100) 416 97 (95–98) 95 (91–98) 99 (98–100)
65–69 465 97 (96–99) 98 (97–100) 97 (94–99) 383 97 (95–98) 98 (95–100) 96 (94–99)
70–74 411 100 (99–100) 100 (99–100) 100 (99–100) 330 97 (95–99) 97 (95–100) 97 (93–100)
75–79 329 99 (98–100) 99 (97–100) 99 (98–100) 263 98 (96–100) 97 (94–100) 99 (98–100)
*

Table footnotes: In boldface the ages (4–5 months, 6–9 months, 6, 7, 8, 15, 16–18, 19–21 yrs) with a significant difference in seroprevalence between the Pienter1 and Pienter2 study.